Abstract: Deferasirox (ICL670) is a once-daily, orally active iron chelator widely utilized in the management of transfusional iron overload and related conditions. It functions as a tridentate ligand, binding ferric iron (Fe3+) in a 2:1 ratio to facilitate its excretion primarily through the hepatobiliary route. This review synthesizes current literature on the pharmacological activity, molecular mechanism of action, and structure-activity relationship of deferasirox. While highly effective in reducing liver and myocardial iron concentrations, its clinical utility is sometimes limited by adverse effects, including renal and hepatic toxicity, as well as gastrointestinal disturbances. Future perspectives highlight the potential of combination chelation therapies, personalized medicine approaches based on genetic and gender differences, and emerging applications in oncology and inflammation.
1. Introduction
Iron is a crucial element for mammalian cells, but in the absence of physiological mechanisms to excrete excess iron, conditions requiring repeated blood transfusions—such as beta-thalassemia, sickle cell disease, and myelodysplastic syndromes (MDS)—inevitably lead to iron overload [1][4]. The accumulation of toxic iron species, particularly non-transferrin-bound iron (NTBI) and labile plasma iron (LPI), generates reactive oxygen species (ROS) that cause severe tissue damage and organ failure, notably in the liver and heart [4][5]. Iron chelation therapy (ICT) is essential to mitigate this toxicity. Deferasirox (ICL670, marketed as Exjade) was developed as a highly effective, once-daily oral iron chelator to overcome the compliance issues associated with older parenteral therapies like deferoxamine (DFO) [1][14]. Approved by the FDA and EMA as a first-line treatment, deferasirox has become a mainstay in managing chronic iron overload in both transfusion-dependent and non-transfusion-dependent anemias [1][4].
2. Pharmacological Activity
Deferasirox exhibits robust pharmacological activity in reducing systemic iron burdens. Clinical trials have demonstrated its efficacy in significantly lowering serum ferritin levels, liver iron concentration (LIC), and myocardial iron (measured via T2* MRI) [10][11][12]. It is typically administered at doses ranging from 20 to 40 mg/kg/day, providing continuous 24-hour chelation coverage due to its long plasma half-life of 8 to 19 hours [1][2]. Beyond thalassemia, deferasirox is utilized in myelofibrosis (MF) and aplastic anemia (AA), where it not only reduces iron toxicity but may also improve erythroid responses and overall survival [4]. Furthermore, deferasirox has shown synergistic pharmacological effects when combined with other therapeutic agents. For instance, it enhances the efficacy of the JAK1/JAK2 inhibitor ruxolitinib in MF, works synergistically with eltrombopag to mobilize cellular iron, and exhibits additive effects with demethylating agents like azacitidine and decitabine in MDS [4].
3. Molecular Mechanism of Action
At the molecular level, deferasirox acts by targeting cytosolic iron, preventing its incorporation into storage proteins like ferritin and hemosiderin [3]. It is a tridentate chelator, meaning two molecules of deferasirox are required to form a stable complex with a single ferric iron atom (Fe3+) in a 2:1 molar ratio [1][9]. The drug has a highly specific affinity for Fe3+ and a significantly lower affinity for other physiologically important divalent cations such as calcium and magnesium [6]. By sequestering free iron, deferasirox effectively neutralizes its redox activity, thereby halting the iron-catalyzed Fenton reactions that produce damaging ROS [4]. This reduction in oxidative stress is critical for preventing cellular apoptosis and tissue fibrosis in iron-loaded organs.
4. Structure-Activity Relationship (SAR)
Deferasirox (4-[3,5-bis-(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid) has a molecular weight of 373.4 Da and carries a negative charge at physiological pH (pH 7.4) [2][9]. Its lipophilic nature allows it to be highly bioavailable orally and to firmly attach to plasma proteins, particularly albumin [1][14]. The structural design facilitates its primary metabolism in the liver via glucuronidation, predominantly mediated by the UGT1A1 enzyme, forming the metabolites M3 (acyl glucuronide) and M6 (2-O-glucuronide) [1]. A minor fraction (approximately 6%) is metabolized by cytochrome P450 enzymes (CYP1A1, CYP1A2, CYP2D6) [1]. The deferasirox-iron complex is excreted almost exclusively through the hepatobiliary system into the feces via the multidrug resistance protein 2 (MRP2/ABCC2), with less than 0.1% eliminated in the urine [1][2]. Notably, its specific structural and charge properties restrict its ability to cross the blood-brain barrier (BBB), limiting its direct application in neurodegenerative diseases characterized by brain iron accumulation [15].
5. Current Limitations
Despite its efficacy, deferasirox therapy is constrained by several adverse drug reactions and limitations. The most common side effects include gastrointestinal disturbances (nausea, vomiting, diarrhea, and abdominal pain) and mild to severe skin rashes [1][4]. More severe toxicities involve renal impairment, characterized by non-progressive increases in serum creatinine, acute kidney injury, and occasionally Fanconi syndrome [1][4][7]. Hepatic toxicity, including elevated transaminases and rare cases of fulminant liver failure, necessitates careful monitoring, particularly in patients with pre-existing hepatic comorbidities [1][4][7]. Cytopenias, such as agranulocytosis and neutropenia, have also been reported [1]. Furthermore, genetic polymorphisms in metabolizing enzymes (e.g., UGT1A1) and transporters (e.g., ABCC2, ABCG2) can significantly influence drug pharmacokinetics, leading to variable therapeutic responses and heightened toxicity in certain individuals [1][8].
6. Future Perspectives
The future of deferasirox therapy lies in optimizing its use through personalized medicine and combination regimens. Tailoring dosages based on genetic profiling (e.g., UGT1A1 polymorphisms) and accounting for sex and gender differences in pharmacokinetics could maximize efficacy while minimizing toxicity [1][10]. Combination chelation therapy—utilizing deferasirox alongside deferoxamine or deferiprone—is emerging as a powerful strategy to achieve negative iron balance and rapid clearance of cardiac and hepatic iron in heavily overloaded patients who fail monotherapy [5][8][13]. Beyond traditional iron overload, deferasirox is being explored for novel applications. Its ability to modulate iron-dependent inflammatory pathways and induce severe mitochondrial swelling in cancer cells highlights its potential as an anti-inflammatory agent and an adjuvant in oncology [3][7]. Continued research into these alternative mechanisms, including its role in modulating ferroptosis, may expand the clinical footprint of deferasirox into new therapeutic arenas [5].
